cadazolid

Cadazolid is an investigational oral antibiotic that combines the pharmacophores of oxazolidinone and fluoroquinolone classes. Developed by Actelion Pharmaceuticals, it was designed to treat Clostridioides difficile infection (CDI), a major cause of drug-resistant diarrhea in the elderly. Cadazolid acts primarily by inhibiting bacterial protein synthesis via binding to the 50S ribosomal subunit, thereby blocking toxin production and spore formation in C. difficile. It is poorly absorbed from the gastrointestinal tract, resulting in high local concentrations in the colon with minimal systemic exposure. Despite promising results in early clinical trials and receiving both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA for CDI, development was discontinued after Phase III trials failed to demonstrate non-inferiority or superiority over vancomycin for clinical cure or sustained cure endpoints[1][2][3][4][5][6][7].

Other names

cadazolid